WindMIL Therapeutics
Princeton, US · Founded 2015 · Delaware corporation · 9 employees on LinkedIn · 1 known investors
Find your way into WindMIL Therapeutics
161 people in our graph share verified history with the WindMIL Therapeutics team — schools, employers, funds. One of them is your warm intro.
WindMIL Therapeutics is a clinical-stage biotechnology company developing cell-based immuno-oncology therapies using marrow-infiltrating lymphocytes (MILs), T cells extracted from a cancer patient's bone marrow that are activated and expanded before being returned to the patient. The company has exclusively licensed the underlying patents and know-how for MILs therapy from Johns Hopkins University.
Founders & leadership
WindMIL Therapeutics was founded in 2015 by Ivan Borrello and Kimberly Noonan.
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$44.9M disclosed across 3 rounds · 2016–2021
▶$2.3MraisedFeb 2021 · 11 investors · BiotechnologyRule 506(b)
- Donald J. Hayden, Jr.Executive Officer, Director
- Patrick FabbioExecutive Officer
- Howard SouleDirector
- Daniel O'DonnellDirector
- Mark McDadeDirector
- Anna FrenchDirector
- Brian DoveyDirector
- Offering amount
- $5M
- Amount sold
- $2.3M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$32.5MraisedJun 2018 · 11 investors · BiotechnologyRule 506(b)
- Allan FoxDirector
- Howard SouleDirector
- Donald Hayden, Jr.Director
- Brian DoveyDirector
- Brian HalakExecutive Officer, Director
- Offering amount
- $32.5M
- Amount sold
- $32.5M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$10MraisedApr 2016 · 4 investors · BiotechnologyRule 506(b)
- Brian HalakExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does WindMIL Therapeutics do?
- WindMIL Therapeutics is a clinical-stage biotechnology company developing cell-based immuno-oncology therapies using marrow-infiltrating lymphocytes (MILs), T cells extracted from a cancer patient's bone marrow that are activated and expanded before being returned to the patient. The company has exclusively licensed the underlying patents and know-how for MILs therapy from Johns Hopkins University.
- Who founded WindMIL Therapeutics?
- WindMIL Therapeutics was founded by Ivan Borrello, Kimberly Noonan in 2015.
- Who are WindMIL Therapeutics's investors?
- WindMIL Therapeutics's investors include Qiming Healthcare.
- How much funding has WindMIL Therapeutics raised?
- WindMIL Therapeutics has disclosed $44.9M raised across 3 rounds.
- Where is WindMIL Therapeutics headquartered?
- WindMIL Therapeutics is headquartered in Princeton, US.